Back

In vivo KCNQ1-suppression-replacement gene therapy in transgenic rabbits with type 1 long QT syndrome

17 April 2023 (09:21 - 09:30)
Organised by:
Congress Presentation Part of: Basic Science Ion Channels, Electrophysiology EHRA Premium Access EHRA 2023

About the speaker

Photo
Doctor Lucilla Giammarino

Mayo Clinic Hospital-Rochester, Rochester (United States of America)

6 More presentations in this session

Presentation thumbnail
Decreasing microtubule detyrosination by parthenolide restores sodium current in mdx cardiomyocytes
Associate Professor C. Remme (Amsterdam, NL)
Abstract Slides Video
Presentation thumbnail
Etiological and molecular determinants of atrial endomysial fibrosis: results from the CATCH ME consortium
Mr J. Winters (Maastricht, NL)
Abstract Slides Video
Presentation thumbnail
Exosome-mediated targeted delivery of NOX4 siRNA ameliorates angiotensin II-induced atrial fibrillation in mice
Ms J. Kang (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Association between CHARGE-AF risk score and LA mechanics: LA reservoir strain can be a single parameter for predicting AF risk
Abstract Slides Video
Presentation thumbnail
In silico biatrial fibrosis ablation improves atrial fibrillation outcome
Doctor C. Roney (London, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Basic Science
Video

The Event

Event poster

EHRA 2023

17 April 2023 09:21 CET
You may be interested in
thumbnail
Congress Presentation
In vivo KCNH2-suppression-replacement gene therapy attenuates the pathogenic phenotype in transgenic rabbits with short QT syndrome type 1
thumbnail
Congress Presentation
Gene therapy for short QT syndrome type 1 (SQT1): a proof-of-concept efficacy trial in transgenic SQT1 rabbits
thumbnail
Congress Presentation
Gene therapy approaches to restore normal cardiac repolarisation and prevent arrhythmias in QT syndromes

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources